Research explained

New studies on GLP-1s, diabetes, and weight, read for you and explained in plain English, with the fine print.

Most recent articles in Research explained

Bar chart of weight lost if people stayed on treatment, each next to its trial's placebo: cagrilintide Phase 2 10.8% vs 3.0%, cagrilintide alone in REDEFINE 1 11.8% vs 2.3%, cagrilintide alone in type 2 diabetes (REIMAGINE 2) 8.4% vs 1.5%, eloralintide Phase 2 20.1% vs 0.4%, eloralintide alone in type 2 diabetes 12.3% vs 3.0%

Research9 min read

Cagrilintide vs Eloralintide: The Two Amylin Shots Compared (2026)

Cagrilintide vs eloralintide: eloralintide hit 20.1% weight loss at 48 weeks, cagrilintide alone 11.8% at 68 weeks. Every trial compared, plus the caveat.

Read the article

Bar chart of tradipitant Study 3601 results: any vomiting 43.0% vs 58.5% on placebo after one untitrated 1 mg semaglutide dose

Research6 min read

Tradipitant for GLP-1 Nausea and Vomiting: Phase 3 Results (2026)

Tradipitant for GLP-1 vomiting: in Phase 3, 43% vomited vs 58.5% on placebo after one untitrated semaglutide dose. What it means and what's unknown.

Read the article

Bar chart of planned enrollment in eloralintide Phase 3 trials: ENLIGHTEN-1 1,980, ENLIGHTEN-2 1,035, ENLIGHTEN-10 3,000

Research5 min read

Eloralintide Phase 3: ENLIGHTEN-10 Adds a 3,000-Person Trial (2026)

Eloralintide Phase 3: Lilly's ENLIGHTEN-10 tests it against placebo in 3,000 adults with type 2 diabetes and heart risk. What it measures and when.

Read the article

Research explained

Most recent articles in Research explained

Cagrilintide vs Eloralintide: The Two Amylin Shots Compared (2026)

Tradipitant for GLP-1 Nausea and Vomiting: Phase 3 Results (2026)

Eloralintide Phase 3: ENLIGHTEN-10 Adds a 3,000-Person Trial (2026)

Other categories you might like

Book summaries

Eating habits

MealCam